Thursday, May 23, 2019 11:01:47 PM
Al4door,
I believe your situation as described, which motivates you to stay the course, is similar to what Linda Powers is motivated by. I believed early on that she would do whatever it takes to get patients a better treatment and off of untargeted chemo and radiation at some point in development. The "gauntlet" has always been the greatest challenge to validation of NWBO's and UCLA's science and long term longs have watched and endured this process. Many here have done this at least in part in tribute to those who suffered through the painful option of chemo/rad vs doing nothing in the hope of a better day ahead. Glad to be here with you in support of the promising nature of that hope. Those syringes of DCVax-L in Dr. Linda Liau's hand, the blinded data and all those patient testimonies give us good reason for that hope. Dr. Ashkan's impatience also gives us reason to believe. Best wishes.
I believe your situation as described, which motivates you to stay the course, is similar to what Linda Powers is motivated by. I believed early on that she would do whatever it takes to get patients a better treatment and off of untargeted chemo and radiation at some point in development. The "gauntlet" has always been the greatest challenge to validation of NWBO's and UCLA's science and long term longs have watched and endured this process. Many here have done this at least in part in tribute to those who suffered through the painful option of chemo/rad vs doing nothing in the hope of a better day ahead. Glad to be here with you in support of the promising nature of that hope. Those syringes of DCVax-L in Dr. Linda Liau's hand, the blinded data and all those patient testimonies give us good reason for that hope. Dr. Ashkan's impatience also gives us reason to believe. Best wishes.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
